Missing data in clinical trials for weight management.
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In 2014, the US FDA approved liraglutide for weight management. The statistical review of the application presented various challenges related to the handling of missing data. The ability of the drug to cause weight loss was not in question. The challenge centered on obtaining a reliable estimate of the intention-to-treat effect to support the risk-benefit evaluation. Subjects in the trials that stopped treatment prior to the endpoint were encouraged to attend the primary endpoint visit. Data from the subjects that returned for a primary efficacy assessment played a significant role in the statistical review. They were used to illustrate shortcomings of the applicant's primary efficacy analysis and sensitivity analyses. They were also used in the FDA analyses to address missing data. The goal of this article is to illustrate challenges and considerations associated with the handling of missing data in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Missing data were imputed with a multiple imputation approach, similar to that described by McEvoy.19 Missing body weight measurements were imputed by sampling from available measurements at week 68 from participants receiving randomized treatment in the relevant randomized treatment group.Missing values were multiply imputed (× 1000).”
Citations
Cites
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884 · cited 3×
“NAS recommended against use of LOCF in the primary analysis unless scientifically justified (NRC, 2010).”
MethodThe Prevention and Treatment of Missing Data in Clinical Trials
(2010) · National Academies Press eBooks · doi:10.17226/12955 · Cited by 438
Carpenter, J. R., Roger, J. H., & Kenward, M. G. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.834911 · Cited by 286 · cited 1×
“This approach was similar to the copy reference (CR) referenced-based imputation strategy that has become popular in recent years (Carpenter et al., 2013), and therefore was of particular interest.”
ResultClinical Trials with Missing Data
O’Kelly, M., & Ratitch, B. (2014) · Wiley eBooks · doi:10.1002/9781118762516 · Cited by 120 · cited 1×
“See O’Kelly and Ratitch (2014) for additional discussion and examples.”
BackgroundA structured approach to choosing estimands and estimators in longitudinal clinical trials
Mallinckrodt, C. H., Lin, Q., Lipkovich, I. A., & Molenberghs, G. (2012) · Pharmaceutical Statistics · doi:10.1002/pst.1536 · Cited by 51 · cited 1×
“This estimand relies on describing what would happen to a subject if they adhered to the study treatment, counter to fact they could not (Mallinckrodt et al., 2012).”
Background
Research works printed but not linked: 1
- Ware J., 2003, NEJM, 348, 2316
Cited by
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Metadata
- Authors
- McEvoy, B. W.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- McEvoy, Bradley W.
- Venue
- Journal of Biopharmaceutical Statistics
- Publisher
- Informa UK Limited
- Published
- 2015-09-29
- Volume
- 26
- Issue
- 1
- Pages
- 30-36
- ISSN
- 1054-3406 (ISSN-L)
- 1520-5711
- OpenAlex
- W2273991054
- Cited by
- 27
- References
- 6
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 1 · 2019: 1 · 2017: 1
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Biopharmaceutical Statistics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Bayesian Inference
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- missing data, liraglutide, weight management, intention-to-treat effect, sensitivity analysis, risk-benefit assessment, weight loss
- MeSH terms
- Clinical Trials as Topic, Data Interpretation, Statistical, Humans, Research Design, United States, United States Food and Drug Administration, Risk Assessment, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Missing data in clinical trials for weight management. https://app.cochat.ai/papers/10.1080/10543406.2015.1094814
- The paper
- McEvoy, B. W. (2016). Missing data in clinical trials for weight management. Journal of Biopharmaceutical Statistics. https://doi.org/10.1080/10543406.2015.1094814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.